Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer

Breast Cancer, Sentinel Nodes

Technetium Tc 99m Sulfur Colloid Injection, Sentinel Nodes, Breast Cancer, Self-Controlled Clinical Trial

The aim of the study is a prospective multicentre phase-3 study that aims to evaluate the detection rate of sentinel lymph node in patients with breast cancer. To compare the detection rates of Technetium Tc 99m Sulfur Colloid Injection(99mTc-SC) and Mitoxantrone Hydrochloride Injection for Tracing(MHI) for lymphatic tracing in patients with breast cancer.

All enrolled subjects with breast cancer will receive Technetium Tc 99m Sulfur Colloid Injection and Mitoxantrone Hydrochloride Injection for Tracing sequentially, to evaluate the efficacy of the two methods for sentinel lymph node (SLN) mapping in breast cancer patients. Due to the characteristics of the investigational product and sentinel lymph node biopsy (SLNB) procedure, blinding is not feasible for this trial; therefore, an open-label design is adopted. At least 8 subjects will be enrolled in the initial exploratory phase to investigate the lymph node uptake of 99mTc-SC, and to determine the optimal administration time, dosage, and preoperative SPECT/CT imaging schedule. These 8 subjects will not be included in the final efficacy and safety analysis set, and an additional 8 subjects will be enrolled subsequently. * At least 4 subjects will receive no more than 0.5 mCi of Technetium Tc 99m Sulfur Colloid Injection at 6 h ± 36 min before surgery. Dynamic scintigraphy (5 min per frame, with supplementary lateral imaging of the ipsilateral side) will be performed for 60 minutes as soon as possible (2-3 min) after injection. Planar static imaging (anterior and ipsilateral lateral views) of the ipsilateral breast and axillary regions will be conducted at 2 h ± 12 min and 3 h ± 18 min, and SPECT/CT imaging (anterior view, ipsilateral lateral view, and tomographic scan) will be performed at 5 h ± 30 min, for a total of 4 scans. * At least 4 subjects will receive no more than 1 mCi of Technetium Tc 99m Sulfur Colloid Injection at 18 h ± 120 min before surgery. Dynamic scintigraphy within 60 minutes (5 min per frame, with supplementary lateral imaging of the ipsilateral side) will be acquired as soon as possible (2-3 min) after injection. Planar static imaging (anterior and ipsilateral lateral views) of the ipsilateral breast and axillary regions will be performed at 2 h ± 12 min, 3 h ± 18 min and 6 h ± 36 min, and SPECT/CT imaging (anterior view, ipsilateral lateral view, and tomographic scan) will be conducted at 18 h ± 120 min, for a total of 5 scans. For the remaining subjects, procedures will be implemented based on the exploratory results from the aforementioned 8 subjects: 1. For subjects undergoing same-day SLNB: 0.5 mCi of 99mTc-SC will be administered; SPECT/CT imaging will be performed at 2 h ± 12 min to 5 h ± 30 min after dosing, and SLNB will be conducted at 3-6 h ± 36 min after dosing. 2. For subjects undergoing next-day SLNB: 1 mCi of 99mTc-SC will be administered; SPECT/CT imaging will be performed at 3 h ± 30 min to 18 h ± 120 min after dosing, and SLNB will be completed within 18 h ± 120 min after dosing. Technetium Tc 99m Sulfur Colloid Injection will be injected subcutaneously over the tumor surface. For subjects with an excisional biopsy cavity, or with tumors located in the upper outer quadrant close to the axilla which may interfere with imaging, subareolar injection is recommended (surgeons are advised to perform preoperative skin marking based on clinical conditions and confirm the appropriate injection site through consultation with the nuclear medicine department). Approximately 15 minutes before surgery, all subjects will receive 0.5-2 mL (5.0 mg/mL) of Mitoxantrone Hydrochloride Injection for Tracing. For subjects undergoing total mastectomy, the injection will be administered subcutaneously around the tumor or posterior to the areola; for subjects undergoing breast-conserving surgery, the injection will be administered via two deep peritumoral subcutaneous injection points or a single point with multi-directional injection (intradermal injection and injection into the areolar area are strictly prohibited). After injection, the injection site will be massaged for 5-8 minutes, followed by sentinel lymph node biopsy. A hand-held gamma probe will then be used to locate "hot spot" lymph nodes and mark their surface positions. An incision will be made along the skin crease over the "hot spot" lymph node, or via the total mastectomy surgical incision, to perform SLNB. Guided by the hand-held gamma probe within the incision, "hot spot" lymph nodes will be resected until no further "hot spots" are detected (radioactive count no higher than 1/10 of the maximum ex vivo SLN count). Meanwhile, blue-stained lymph nodes will be identified and removed. Subsequently, total mastectomy or breast-conserving surgery will be performed, and all blue-stained tissues will be resected as thoroughly as possible intraoperatively. Resected lymph nodes with radioactive uptake and/or blue staining are defined as SLNs. Clinically suspicious lymph nodes that are neither "hot spots" nor blue-stained will also be resected and labeled separately. The in vivo radioactive counts of "hot spots" and ex vivo radioactive counts of SLNs will be recorded. The following quantities will all be documented: the number of SLNs positive for both radioactive "hot spot" and blue staining, the number of SLNs positive only for radioactive "hot spot", the number positive only for blue staining, and the number of suspicious SLNs negative for both radioactive "hot spot" and blue staining. Both intraoperative pathological diagnosis and postoperative pathological diagnosis of breast cancer SLNs are acceptable in this study. Pathological examination will be performed in accordance with the standard procedures of each investigational center, and the pathological diagnosis of each sentinel lymph node will be recorded. * Intraoperative pathological examination: Intraoperative SLN specimens will be sectioned into 2 mm-thick frozen sections. A portion of the tissue will be used for intraoperative histopathological examination with hematoxylin and eosin (HE) staining; the remaining tissue sections will be processed for routine paraffin pathological examination after surgery, with HE staining and immunohistochemistry (IHC, if indicated). In case of discrepancy between intraoperative and postoperative pathology for an individual subject, the positive pathological result shall prevail. * Postoperative pathological examination: All resected SLN tissues will be sampled and prepared into paraffin-embedded sections, sectioned at 2 mm thickness, and subjected to HE staining and immunohistochemistry (if indicated). SLN metastasis will be classified according to the AJCC Cancer Staging Manual, 8th Edition. In this study, a positive SLN is defined as metastatic foci with a maximum diameter \> 0.2 mm detected by histological examination or immunohistochemistry. A positive subject refers to a patient in whom at least one positive SLN is identified.

No related papers found yet.

China